One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Cardiomyopathies and myocardial fibrosis: diagnostic and therapeutic challenges
Filippo Crea
doi : 10.1093/eurheartj/ehac688
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4665–4668
Left atrial appendage occluders—new hope for stroke prevention in high-risk patients
Pavel Osmancik, Petr Widimsky
doi : 10.1093/eurheartj/ehac382
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4669–4671
Eggs and the heart
Franz H Messerli, Wanpen Vongpatanasin, Adrian W Messerli
doi : 10.1093/eurheartj/ehac473
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4672–4674
The RUHR Heart Failure Network: improved heart failure care in a metropolitan area
Peter Luedike, Gerd Heusch, Tienush Rassaf
doi : 10.1093/eurheartj/ehac480
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4675–4676
Mind the map: a multi-omic approach to post-ischaemic cardiac remodelling paves the way for future cardiovascular research
Daniela Pedicino, Giovanna Liuzzo
doi : 10.1093/eurheartj/ehac525
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4677–4678
Restrictive cardiomyopathy: definition and diagnosis
Claudio Rapezzi, Alberto Aimo, Andrea Barison, Michele Emdin, Aldostefano Porcari, Ales Linhart, Andre Keren, Marco Merlo, Gianfranco Sinagra
doi : 10.1093/eurheartj/ehac543
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4679–4693
Restrictive cardiomyopathy (RCM) is a heterogeneous group of diseases characterized by restrictive left ventricular pathophysiology, i.e. a rapid rise in ventricular pressure with only small increases in filling volume due to increased myocardial stiffness.
Highly malignant disease in childhood-onset arrhythmogenic right ventricular cardiomyopathy
Marit Kristine Smedsrud, Monica Chivulescu, Marianne Inngjerdingen Forså, Isotta Castrini, Eivind Westrum Aabel, Christine Rootwelt-Norberg, Martin Prøven Bogsrud, Thor Edvardsen, Nina Eide Hasselberg, Andreas Früh, Kristina Hermann Haugaa
doi : 10.1093/eurheartj/ehac485
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4694–4703
This study aimed to explore the incidence of severe cardiac events in paediatric arrhythmogenic right ventricular cardiomyopathy (ARVC) patients and ARVC penetrance in paediatric relatives. Furthermore, the phenotype in childhood-onset ARVC was described.
Arrhythmogenic cardiomyopathies in children: seek and you shall find
Juan Pablo Kaski
doi : 10.1093/eurheartj/ehac585
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4704–4706
Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci
Jonas Ghouse, Vinicius Tragante, Ayesha Muhammad, Gustav Ahlberg, Morten W Skov, Dan M Roden, Ingileif Jonsdottir, Laura Andreasen, Pia Rengtved Lundegaard, Linea C Trudsø, Karina Banasik, Søren Brunak, Sisse R Ostrowski, eMERGE consortium, Christian Torp-Pedersen, Ole V Pedersen, Erik Sørensen, Lars Køber, Kasper Iversen, Unnur Thorsteinsdottir, Gudmundur Thorgeirsson, Henrik Ullum, Daniel F Gudbjartsson, Jonathan D Mosley, Hilma Holm, Kari Stefansson, Henning Bundgaard, Morten Salling Olesen
doi : 10.1093/eurheartj/ehac322
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4707–4718
To search for sequence variants associated with ACEi discontinuation and to test their association with ACEi-associated adverse drug reactions (ADRs).
Toward personalized medicine for cardiovascular pharmacotherapy
Juan Tamargo, Koji Hasegawa, Stefan Agewall
doi : 10.1093/eurheartj/ehac413
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4719–4721
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment
Ana Martinez-Naharro, Rishi Patel, Tushar Kotecha, Nina Karia, Adam Ioannou, Aviva Petrie, Liza A Chacko, Yousuf Razvi, Sriram Ravichandran, James Brown, Steven Law, Cristina Quarta, Shameem Mahmood, Brendan Wisniowski, Silvia Pica, Sajitha Sachchithanantham, Helen J Lachmann, James C Moon, Daniel S Knight, Carol Whelan, Lucia Venneri, Hui Xue, Peter Kellman, Julian D Gillmore, Philip N Hawkins, Ashutosh D Wechalekar, Marianna Fontana
doi : 10.1093/eurheartj/ehac363
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4722–4735
To assess the ability of cardiovascular magnetic resonance (CMR) to (i) measure changes in response to chemotherapy; (ii) assess the correlation between haematological response and changes in extracellular volume (ECV); and (iii) assess the association between changes in ECV and prognosis over and above existing predictors.
The challenge of managing patients with light-chain cardiac amyloidosis: the value of cardiac magnetic resonance as a guide to the treatment response
Thibaud Damy, Amira Zaroui, Silvia Oghina
doi : 10.1093/eurheartj/ehac526
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4736–4738
Scleraxis and fibrosis in the pressure-overloaded heart
Raghu S Nagalingam, Sikta Chattopadhyaya, Danah S Al-Hattab, David Y C Cheung, Leah Y Schwartz, Sayantan Jana, Nina Aroutiounova, D Allison Ledingham, Teri L Moffatt, Natalie M Landry, Rushita A Bagchi, Ian M C Dixon, Jeffrey T Wigle, Gavin Y Oudit, Zamaneh Kassiri, Davinder S Jassal, Michael P Czubryt
doi : 10.1093/eurheartj/ehac362
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4739–4750
In response to pro-fibrotic signals, scleraxis regulates cardiac fibroblast activation in vitro via transcriptional control of key fibrosis genes such as collagen and fibronectin; however, its role in vivo is unknown. The present study assessed the impact of scleraxis loss on fibroblast activation, cardiac fibrosis, and dysfunction in pressure overload-induced heart failure.
Targeting a transcriptional scleraxis to treat cardiac fibrosis
Alexander R H Hobby, Timothy A McKinsey
doi : 10.1093/eurheartj/ehac608
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4751–4753
Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
Bertram Pitt, Deepak L Bhatt, Marco Metra
doi : 10.1093/eurheartj/ehac417
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4754–4757
Immunosuppressive therapy of myocarditis and inflammatory cardiomyopathy in the light of new data
Krzysztof Ozieranski, Agata Tyminska, Alida L P Caforio
doi : 10.1093/eurheartj/ehac500
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Pages 4758–4759
Individualized immunosuppression in virus-negative inflammatory cardiomyopathy
Andrea Frustaci, Matteo A Russo, Cristina Chimenti
doi : 10.1093/eurheartj/ehac559
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Page 4760
A case of posterior mediastinal cyst misdiagnosed as left atrial dissection
Li Dong, Yafeng He, Xiaojing Ma
doi : 10.1093/eurheartj/ehac564
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Page 4761
Fusion imaging in preoperative planning of mitral valve surgery to prevent injury of the left circumflex artery
Jelle Piet Man, Berto Jorrit Bouma, Mark Johan Schuuring
doi : 10.1093/eurheartj/ehac566
European Heart Journal, Volume 43, Issue 45, 1 December 2022, Page 4762
